Renal cell carcinoma – Diagnostics – Overview of Information and Clinical Research

Diagnosing renal cell carcinoma involves several important steps, from recognizing when to seek medical help to performing detailed tests that confirm the disease and determine its stage. Often, this kidney cancer causes no symptoms in its early stages, meaning many tumors are discovered unexpectedly during scans done for other reasons.

Introduction: Who Should Undergo Diagnostics

Most people with renal cell carcinoma don’t notice anything wrong in the early stages of the disease. The cancer can grow silently inside the kidney without causing pain or other warning signs. This makes it particularly important to pay attention to certain symptoms when they do appear, even if they seem mild or unrelated to your kidneys^[1].

You should seek medical evaluation if you notice blood in your urine, even if it appears only once or twice. This symptom, called hematuria (visible blood in urine), can be an important warning sign. Other reasons to contact your healthcare provider include persistent pain in your sides or lower back that doesn’t go away with rest, unexplained weight loss without trying to lose weight, or a lump or mass you can feel in your abdomen or side. Fever that comes and goes without an obvious cause, frequent night sweats, and ongoing fatigue that interferes with daily activities are also symptoms that warrant medical attention^[1]^[2].

Certain people face higher risks and might benefit from being more alert to changes in their health. If you smoke or have smoked in the past, your risk increases significantly. Being overweight, having high blood pressure that requires medication, or receiving long-term dialysis treatment for kidney problems are all factors that increase your chances of developing renal cell carcinoma. People with a family history of kidney cancer or certain inherited conditions, such as von Hippel-Lindau disease, should be especially vigilant about reporting any unusual symptoms to their doctor^[3]^[4].

⚠️ Important

Many kidney tumors are found accidentally when doctors perform imaging tests like CT scans or ultrasounds for completely unrelated reasons. This is actually quite common and can be fortunate, as finding the cancer early often leads to better outcomes. Don’t be alarmed if a kidney mass is discovered during a test for back pain or digestive problems.

Diagnostic Methods

When you visit your doctor with symptoms that might suggest kidney cancer, the diagnostic process typically begins with a thorough conversation about your health history and a physical examination. Your doctor will ask detailed questions about when you first noticed symptoms, whether they’ve gotten worse, what makes them better or worse, and whether you have any of the risk factors mentioned earlier. During the physical exam, your doctor will feel your abdomen and sides to check for lumps or swelling and look for other signs that might indicate kidney problems^[9].

Following the initial examination, your healthcare provider will order blood tests and urine tests. Blood tests help doctors understand how well your kidneys are working and can reveal other important information about your overall health. A complete blood count (which measures different types of blood cells) might show anemia, a condition where you don’t have enough red blood cells, which sometimes occurs with kidney cancer. Blood chemistry tests check levels of various substances in your blood that can indicate kidney function. Liver function tests may also be performed because kidney cancer can sometimes affect the liver^[7]^[9].

Urine tests, formally called urinalysis, are essential because they can detect blood in the urine that isn’t visible to the naked eye. Even when you can’t see blood, laboratory testing might reveal small amounts of red blood cells in your urine sample. The test also looks for other substances or abnormalities that might indicate kidney disease or other problems^[7].

The most important diagnostic tools for renal cell carcinoma are imaging tests, which create pictures of the inside of your body. An ultrasound of the abdomen and kidneys is often one of the first imaging tests performed. This test uses sound waves to create images and is painless and non-invasive. It can show whether a mass in the kidney is solid (which might be cancer) or filled with fluid (which is usually a harmless cyst)^[7]^[9].

A CT scan (computed tomography scan) is usually the most detailed imaging test for diagnosing kidney cancer. This test uses X-rays taken from many angles and combines them with computer processing to create cross-sectional images of your kidneys and surrounding structures. The CT scan can show the size and location of a tumor, whether it has grown into nearby blood vessels, and whether cancer has spread to lymph nodes or other organs. Sometimes you’ll receive a contrast dye through an IV before the scan to make the images clearer. This dye helps doctors see blood vessels and kidney tissue more clearly^[7]^[12].

Magnetic resonance imaging, or MRI, is another imaging option that uses magnets and radio waves instead of X-rays to create detailed pictures of your kidneys. MRI can be especially helpful if your doctor needs more information after a CT scan, or if you can’t have the contrast dye used in CT scans due to kidney problems or allergies. Like CT scans, MRI can show the size and location of tumors and whether cancer has spread^[7]^[12].

An intravenous pyelogram, or IVP, is an older type of X-ray test where contrast dye is injected into a vein and then X-rays are taken as the dye travels through your kidneys. While this test is used less frequently now because CT and MRI provide more detailed information, it may still be performed in some situations^[7].

In many cases, doctors can diagnose kidney cancer based on imaging tests alone without needing to perform a biopsy (removing a small piece of tissue to examine under a microscope). However, sometimes a biopsy is necessary to confirm the diagnosis or determine the specific type of kidney cancer. During a kidney biopsy, a thin needle is inserted through your skin into the kidney to remove a small sample of the tumor. This procedure is usually done with local anesthesia and imaging guidance to ensure the needle reaches the right spot. The tissue sample is then examined by a pathologist, a doctor who specializes in diagnosing diseases by looking at cells and tissues^[7]^[12].

If imaging tests suggest that kidney cancer may have spread to other parts of your body, additional tests might be ordered. A chest X-ray or chest CT scan can check whether cancer has spread to the lungs, which is one of the more common places where kidney cancer spreads. A bone scan might be performed if you have bone pain or if blood tests suggest bone involvement. For a bone scan, a small amount of radioactive material is injected into your vein, and after a few hours, a special camera takes pictures of your entire skeleton to look for areas where cancer might have spread. In some cases, a PET scan (positron emission tomography) might be used to look for cancer throughout the body^[7]^[9].

Once renal cell carcinoma is diagnosed, doctors determine the stage of the cancer, which describes how large the tumor is and whether it has spread beyond the kidney. Staging is crucial because it helps doctors decide on the best treatment approach. The staging process uses information from all the diagnostic tests performed. Early-stage cancers (stages 1 and 2) are confined to the kidney. Stage 3 cancer has grown into nearby blood vessels or lymph nodes but hasn’t spread to distant organs. Stage 4 cancer has spread to distant parts of the body such as the lungs, bones, liver, or brain^[7]^[11].

⚠️ Important

If your doctor recommends surgery to remove part or all of your kidney without first doing a biopsy, don’t be surprised. When imaging strongly suggests kidney cancer and the tumor appears localized, many doctors prefer to remove it surgically rather than perform a biopsy first. The removed tissue is then examined to confirm the diagnosis and determine the cancer type.

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments for renal cell carcinoma. If you’re considering joining a clinical trial, you’ll need to undergo specific diagnostic tests to determine whether you qualify for the study. Each clinical trial has its own set of requirements, called eligibility criteria, that determine who can participate. These criteria exist to ensure patient safety and to make sure the study results are meaningful^[14].

Most clinical trials for renal cell carcinoma require recent imaging tests, typically performed within a few weeks before enrollment. These might include CT scans or MRI scans of your chest, abdomen, and pelvis to establish a baseline understanding of where cancer is located in your body and how large the tumors are. These baseline scans will be compared to scans taken during and after treatment to measure whether the treatment is working. Some trials may require PET scans or bone scans as well^[14].

Blood tests are standard requirements for clinical trial participation. Your kidney function must be measured through blood tests that check levels of substances like creatinine and calculate your glomerular filtration rate (GFR), which indicates how well your kidneys are filtering waste. Many trials have minimum kidney function requirements to ensure that patients can safely receive the treatments being tested. Complete blood counts are also required to make sure you have adequate numbers of red blood cells, white blood cells, and platelets before starting treatment^[14].

Liver function tests are another standard requirement because many cancer treatments are processed by the liver. Your blood will be tested for enzymes and other substances that indicate how well your liver is working. Blood chemistry panels check electrolytes and other important values. Some trials also require tests for infectious diseases like hepatitis or HIV, not to exclude people from participation but to ensure they receive appropriate monitoring and care during the trial.

For trials testing new targeted therapies or immunotherapies, you might need additional specialized tests. Tissue samples from your tumor, either from a previous biopsy or surgery, may be analyzed to look for specific genetic changes or protein markers. These biomarker tests help determine whether your particular type of kidney cancer is likely to respond to the treatment being studied. Some trials specifically enroll only patients whose tumors have certain characteristics^[15].

Your overall health status, called performance status, will be assessed using standardized scales that measure your ability to carry out daily activities. This helps determine whether you’re strong enough to tolerate the treatments being tested. You’ll also need to provide detailed information about any other medications you’re taking, as some drugs can interfere with experimental treatments.

Throughout your participation in a clinical trial, you’ll undergo regular monitoring with repeated blood tests, urine tests, and imaging scans at specified intervals. This careful monitoring helps researchers understand how well the treatment works and whether it causes any side effects. The frequency and types of these tests are specified in the trial protocol, and following this schedule closely is an important part of participating in research^[14].

Prognosis and Survival Rate

Prognosis

The outlook for people with renal cell carcinoma depends heavily on several factors, with the stage of cancer at diagnosis being the most important. When the tumor is discovered while it’s still confined to the kidney and hasn’t spread, the prognosis is generally very good. Many people with early-stage disease can be cured with surgery alone. The size of the tumor also matters, with smaller tumors typically associated with better outcomes than larger ones^[1]^[13].

The specific type of renal cell carcinoma affects prognosis as well. Clear cell renal cell carcinoma, the most common type, tends to be more aggressive than some other types like papillary or chromophobe renal cell carcinoma. However, advances in targeted therapies and immunotherapies have significantly improved outcomes even for aggressive types of kidney cancer^[1]^[5].

Your overall health and kidney function also influence your prognosis. People who are otherwise healthy and have good kidney function in their remaining kidney tissue generally do better than those with other health problems. Your age can be a factor, though renal cell carcinoma can occur at any age. The disease is most commonly diagnosed in people aged 60 to 80, and older adults may face additional challenges related to other health conditions^[1].

For advanced or metastatic renal cell carcinoma, where cancer has spread to other organs, the disease becomes much more difficult to treat. While a cure is less likely in these situations, many treatment options are available that can control the cancer, shrink tumors, and relieve symptoms. New therapies, particularly immunotherapy and targeted drugs, have extended survival times and improved quality of life for people with advanced kidney cancer. Some people with metastatic disease live for many years with ongoing treatment^[1]^[15].

Survival Rate

Survival rates for renal cell carcinoma vary significantly based on the stage at diagnosis. When kidney cancer is found while it’s still localized (hasn’t spread beyond the kidney), the five-year survival rate is approximately 93 percent. This means that about 93 out of 100 people diagnosed with localized kidney cancer are still alive five years after diagnosis. These excellent survival rates reflect the effectiveness of surgery and other treatments for early-stage disease^[7].

For people diagnosed with metastatic kidney cancer, where the disease has spread to distant parts of the body like the lungs, bones, or liver, the five-year survival rate is considerably lower, at about 12 percent. However, it’s important to understand that survival rates are statistics based on large groups of people and may not reflect individual circumstances. Many factors can influence an individual’s outcome, and survival rates don’t account for newer treatments that have become available in recent years^[7].

The timing of diagnosis makes an enormous difference. Healthcare providers diagnose approximately 80,000 new cases of renal cell carcinoma each year in the United States and 400,000 new cases worldwide. Many of these cases are found incidentally during imaging tests performed for other reasons, which can lead to earlier detection and better outcomes^[1]^[13].

It’s worth noting that survival rates are based on people diagnosed and treated several years ago and may not reflect the most recent advances in treatment. New immunotherapy drugs and targeted therapies approved in the last few years have shown promise in extending survival for people with advanced kidney cancer, but it takes time for these improvements to be reflected in survival statistics^[15].

#1 Clinical Trials Search in Europe